LYRA vs. PYPD, IINN, NEPH, PAVM, MDAI, NMTC, FEMY, AKLI, MHUA, and RVP
Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include PolyPid (PYPD), Inspira Technologies Oxy B.H.N. (IINN), Nephros (NEPH), PAVmed (PAVM), Spectral AI (MDAI), NeuroOne Medical Technologies (NMTC), Femasys (FEMY), Akili (AKLI), Meihua International Medical Technologies (MHUA), and Retractable Technologies (RVP). These companies are all part of the "surgical & medical instruments" industry.
Lyra Therapeutics (NASDAQ:LYRA) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation.
PolyPid has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -4,099.82%. Lyra Therapeutics' return on equity of -77.34% beat PolyPid's return on equity.
Lyra Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.
In the previous week, Lyra Therapeutics had 25 more articles in the media than PolyPid. MarketBeat recorded 34 mentions for Lyra Therapeutics and 9 mentions for PolyPid. PolyPid's average media sentiment score of 0.78 beat Lyra Therapeutics' score of -0.45 indicating that PolyPid is being referred to more favorably in the news media.
PolyPid has lower revenue, but higher earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.
PolyPid received 1 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 74.19% of users gave PolyPid an outperform vote while only 61.11% of users gave Lyra Therapeutics an outperform vote.
Lyra Therapeutics currently has a consensus price target of $7.13, indicating a potential upside of 1,743.47%. PolyPid has a consensus price target of $14.00, indicating a potential upside of 211.11%. Given Lyra Therapeutics' higher possible upside, equities analysts clearly believe Lyra Therapeutics is more favorable than PolyPid.
95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 17.4% of Lyra Therapeutics shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
PolyPid beats Lyra Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Lyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyra Therapeutics Competitors List
Related Companies and Tools
